Global assessment for quality and safety of control in type 2 diabetic patients

European Journal of Clinical Investigation

Volumn 34, Issue 1, 2004, Pages 37-42

  Monnier, L ^a,b   Colette, C ^b   Lapinski, H ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Extended postlunch glycaemia; Glucose monitoring; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ACCURACY; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SAFETY;

AREA UNDER CURVE; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE;

EID: 1242314789     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01280.x     Document Type: Article

References (24)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26 (Suppl. 1):S33-S50.
3. Faas A, Schellevis FG, Van Eijk JTM. The efficacy of self-monitoring of blood glucose in NIDDM subjects. Diabetes Care 1997;20:1482-6.
4. Wing RR, Eipstein LH, Nowalk MP, Scott N, Koeske R, Hagg S. Does self-monitoring of blood glucose levels improve dietary compliance for obese patients with type II diabetes. Am J Med 1986;81:830-6.
5. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes (Technical Review). Diabetes Care 1995;18:896-909.
6. CIQUAL. Répertoire Général Des Aliments, 2nd edn. Paris, France: Lavoisier;1995.
7. Holland B, Welch AA, Unwin ID, Buss DH, Paul AA, Southgate DAT. Mc Cance and Widdowson's the Composition of Foods, 5th edn. Cambridge, UK: The Royal Society of Chemistry; 1992.
8. Wolever TMS. The glycaemic index: aspects of some vitamins, minerals and enzymes in health and disease. World Rev Nutr Diet 1990;62:120-85.
9. Tsihlias EB, Gibbs AL, McBurney MI, Wolever TMS. Comparison of high-and low-glycemic index breakfast cereals with monounsaturated fat in the long-term dietary management of type 2 diabetes. Am J Clin Nutr 2000;72:439-49.
10. Dinneen S, Gerich JE, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:707-13.
11. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes ? Eur J Clin Invest 2000;30 (Suppl. 2):3-11.
12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
13. Metz CE. Statistical analysis of ROC data in evaluating diagnostic performance. In: Herbert D, Myers R, editors. Multiple Regression Analysis: Application in the Health Science. New York: American Institute of Physics; 1986.pp. 365-84.
14. Monsod TP, Flanagan DE, Rife F, Saenz R, Caprio S, Sherwin RS et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hyperglycemia and hyperinsulinemia? Diabetes Care 2002;25:889-93.
15. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2002;25:750-86.
16. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-5.
17. Avignon A, Radauceanu A, Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6.
18. Turner RC, Holman RR. Insulin use in NIDDM: Rationale based on pathophysiology of disease. Diabetes Care 1990;13:1011-20.
19. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 1994;43:871-7.
20. Trovati M, Burzacca S, Mularoni E, Massuco P, Cavalot F, Mattiello L et al. Occurrence of low blood glucose concentrations during the afternoon in Type 2 (noninsulin-dependent) diabetic patients on oral hypoglycemic agents: importance of blood glucose monitoring. Diabetologia 1991;34:662-7.
21. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21:1897-903.
22. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9.
23. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
24. Feinglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care 1999;22 (Suppl. 3):C61-4.